Home » Stocks » QBIO

Q BioMed Inc. (QBIO)

Stock Price: $0.9310 USD 0.0110 (1.20%)
Updated May 7, 2021 3:51 PM EDT - Market closed
Market Cap 24.32M
Revenue (ttm) 30,000
Net Income (ttm) -11.02M
Shares Out 26.12M
EPS (ttm) -0.47
PE Ratio n/a
Forward PE 111.11
Dividend n/a
Dividend Yield n/a
Trading Day May 7
Last Price $0.9310
Previous Close $0.9200
Change ($) 0.0110
Change (%) 1.20%
Day's Open 0.9200
Day's Range 0.9200 - 0.9500
Day's Volume 26,748
52-Week Range 0.8900 - 2.0500

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

Q BioMed Inc (OTCQB:QBIO) has released a letter to shareholders, bringing them up to speed on the developments of its technology partner, Mannin Research, and its work to treat the coronavirus (COVID-19...

1 week ago - Proactive Investors

NEW YORK, April 27, 2021 /PRNewswire/ -- Q BioMed Inc. (OTCQB: QBIO), a commercial stage biotech company, updates shareholders. In March 2021,it was announced that our technology partner, Mannin Researc...

1 week ago - PRNewsWire

Acquires undervalued biomedical assets to accelerate their development Developing drugs and therapies to treat pediatric nonverbal autism, liver cancer, and glaucoma Produces cancer bone-pain drug Stron...

1 month ago - Proactive Investors

Q BioMed Inc (OTCQB:QBIO) has announced a supply contract with the US Department of Defense and Veterans Affairs (VA), which will make its cancer bone pain drug available to over 9 million VA beneficiar...

2 months ago - Proactive Investors

NEW YORK, March 2, 2021 /PRNewswire/ -- Q BioMed Inc. (OTCQB: QBIO), a commercial stage biotech company, announced today that it has signed an agreement for Strontium89 (Strontium Chloride Sr-89 Injecti...

2 months ago - PRNewsWire

NEW YORK, Feb. 1, 2021 /PRNewswire/ -- Q BioMed Inc. (OTCQB: QBIO), a commercial stage biotech company, announced today that it has been awarded a contract with UroGPO, the largest Group Purchasing Orga...

3 months ago - PRNewsWire

NEW YORK, Jan. 27, 2021 /PRNewswire/ -- Q BioMed Inc. (OTCQB: QBIO), announced today that the U.S. Food and Drug Administration's Office of Orphan Products Development has granted Orphan Drug Designatio...

3 months ago - PRNewsWire

NEW YORK, Dec. 29, 2020 /PRNewswire/ -- Q BioMed Inc. (OTCQB: QBIO), a commercial stage biotech company, today issued a letter to shareholders. Dear Fellow Shareholders, As 2020 draws to a close, we joi...

4 months ago - PRNewsWire

NEW YORK, Dec. 21, 2020 /PRNewswire/ -- Q BioMed, Inc. (OTCQB: QBIO) is pleased to announce that its technology partner Mannin Research Inc. (MRI), a private Canadian biotechnology company, is a member ...

4 months ago - PRNewsWire

About QBIO

Q BioMed Inc., a biomedical acceleration and development company, focuses on licensing, acquiring, and providing resources to life sciences and healthcare companies. The company offers Strontium Chloride SR89, a radiopharmaceutical therapeutic for the treatment of bone cancer pain therapies; and Metastron, a radiopharmaceutical drug for metastatic cancer bone pain therapy. It is also developing Man-01, a pre-clinical lead candidate for the treatment of primary open angle glaucoma; QBM-001 for rare pediatric non-verbal autism spectrum disorder; ... [Read more...]

Industry
Biotechnology
Founded
2013
Stock Exchange
OTCMKTS
Ticker Symbol
QBIO
Full Company Profile

Financial Performance

Financial Statements